Center-Authored Papers

Filters: Author is Small, Eric J  [Clear All Filters]
2009
Hussain M, Goldman B, Tangen CM, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK et al..  2009.  Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(15):2450-6. Abstract
2010
Higano CS, Small EJ, Schellhammer P, Yasothan U, Gubernick S, Kirkpatrick P, Kantoff PW.  2010.  Sipuleucel-T.. Nature reviews. Drug discovery. 9(7):513-4.
2012
Tangen CM, Hussain MHA, Higano CS, Eisenberger MA, Small EJ, Wilding G, Donnelly BJ, Schelhammer PF, Crawford DE, Vogelzang NJ et al..  2012.  Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8494, S8894 and S9346).. The Journal of urology. 188(4):1164-9. Abstract
2013
Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS et al..  2013.  Prostate cancer, version 1.2014.. Journal of the National Comprehensive Cancer Network : JNCCN. 11(12):1471-9. Abstract
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S et al..  2013.  Abiraterone in metastatic prostate cancer without previous chemotherapy.. The New England journal of medicine. 368(2):138-48. Abstract
2014
Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PFA, Mainwaring P, Hainsworth JD et al..  2014.  Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302).. European urology. Abstract
Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS et al..  2014.  Prostate cancer, version 2.2014.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(5):686-718. Abstract
2015
Morris MJ, Molina A, Small EJ, de Bono JS, Logothetis CJ, Fizazi K, de Souza P, Kantoff PW, Higano CS, Li J et al..  2015.  Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(12):1356-63. Abstract
Crawford DE, Petrylak DP, Higano CS, Kibel AS, Kantoff PW, Small EJ, Shore ND, Ferrari A.  2015.  Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer.. The Canadian journal of urology. 22(6):8048-55. Abstract
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ et al..  2015.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet. Oncology. 16(2):152-60. Abstract
GuhaThakurta D, Sheikh NA, Fan L-Q, Kandadi H, Meagher T, Hall SJ, Kantoff P, Higano CS, Small EJ, Gardner TA et al..  2015.  HUMORAL IMMUNE RESPONSE AGAINST NON-TARGETED TUMOR ANTIGENS AFTER TREATMENT WITH SIPULEUCEL-T AND ITS ASSOCIATION WITH IMPROVED CLINICAL OUTCOME.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin M-E, Ryan CJ, Lin AM, Alumkal J, Graff JN, Nordquist LT et al..  2015.  Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With . Clinical genitourinary cancer. 13(3):e191-8. Abstract
2016
Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN et al..  2016.  Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM et al..  2016.  Prostate Cancer, Version 1.2016.. Journal of the National Comprehensive Cancer Network : JNCCN. 14(1):19-30. Abstract
Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M et al..  2016.  Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract